Pierre Fabre Medicament

Institut National De La Sante Et De La Recherche Medicale

Adir Et Compagnie

Universitè De Montpellier

Institut Regional Du Cancer De Montpellier

Gamamabs Pharma Sa

Gamamabs Pharma

Pierre Fabre Medicament Production

Jean-Marc Barret

Thierry Imbert

Yves Guminski

Anna Kruczynski

Jean-François Prost

Olivier Dubreuil

Alain Duflos

Christel Larbouret

Jacques Fahy

André Pelegrin

Jean-Philippe Annereau

Bridget Hill

Delphine Desigaud

Stéphane Degove

Thierry Chardès

Valerie Thillaye Du Boullay

Valérie Thillaye Du Boullay

The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.

Anti-human-HER3 antibodies and uses thereof

This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-M&#xfc;llerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed M&#xfc;llerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.

Antibodies, antibody drug conjugates and methods of use

The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.

(Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents

The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying such tumors in order to adapt their treatment. The derivatives are of the formula (I) or a pharmaceutically acceptable salt thereof, in which: Ris one or more NOgroups in position 4 or 6, or a SOPh, SONMe, SONHor SOH group; Ris hydrogen, Calkyl, benzyl, a perfluoroalkyl group; the values of a, b, c range from 2 to 5 independently from each other and represent alkylene chains separating the amino groups, and the values of d and e can independently be 0 or 1.

Fluorescent derivatives of polyamines, method for preparing same and applications thereof as diagnosis tools in the treatment of cancerous tumors

The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent.

(Poly)Aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents

The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamidc, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent. Formula (1) wherein: &#x2014;R represents hydrogen or Calkyl, &#x2014;A represents CO(CH)or CONH(CH)where n=2, 3, 4, or 5, &#x2014;R1 and R2 are as described herein. 

(Poly) aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents

(Poly)aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents

Vinca alkaloid antimitotic halogenated derivatives

Growing community of inventors

Castres, France

Jean-Marc Barret